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Abstract: The aim of this study was to develop a bioimaging probe based on magnetic iron oxide
nanoparticles (MIONs) surface functionalized with the copolymer (p(MAA-g-EGMA)), which were
radiolabeled with the positron emitter Gallium-68. The synthesis of the hybrid MIONs was realized
by hydrolytic condensation of a single ferrous precursor in the presence of the copolymer. The
synthesized MagP MIONs displayed an average Dh of 87 nm, suitable for passive targeting of
cancerous tissues through the enhanced permeation and retention (EPR) effect after intravenous
administration, while their particularly high magnetic content ascribes strong magnetic properties
to the colloids. Two different approaches were explored to develop MIONs radiolabeled with
68Ga: the chelator-mediated approach, where the chelating agent NODAGA-NHS was conjugated
onto the MIONs (MagP-NODAGA) to form a chelate complex with 68Ga, and the chelator-free
approach, where 68Ga was directly incorporated onto the MIONs (MagP). Both groups of NPs
showed highly efficient radiolabeling with 68Ga, forming constructs which were stable with time,
and in the presence of PBS and human serum. Ex vivo biodistribution studies of [68Ga]Ga- MIONs
showed high accumulation in the mononuclear phagocyte system (MPS) organs and satisfactory
blood retention with time. In vivo PET imaging with [68Ga]Ga-MagP MIONs was in accordance with
the ex vivo biodistribution results. Finally, the MIONs showed low toxicity against 4T1 breast cancer
cells. These detailed studies established that [68Ga]Ga- MIONs exhibit potential for application as
tracers for early cancer detection.
Keywords: Gallium-68; iron oxide nanoparticles; MTT; radiolabeling; biodistribution; PET
1. Introduction
In the pursuit of more effective cancer targeting probes, radiolabeled nanoparticles
have attracted intense scientific interest for their great potential in nuclear medicine. The
unique physical and chemical properties of materials in the nanoscale, such as high sur-
face to volume ratio, magnetic properties, and tunable surface chemistry, have led to the
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development of numerous nanoparticle types of different size, shape, and core material as
versatile platforms for various applications. Nanoparticles labeled with radioisotopes, such
as Technetium-99m [99mTc], Gallium-68 [68Ga], and Zirconium-89 [89Zr], are used as cancer
imaging agents in single photon emission computed tomography (SPECT) and positron
emission tomography (PET) [1–8]. For therapeutic purposes, nanoparticles are radiolabeled
with beta (β)- or alpha (α)-emitting isotopes such as Lutetium-177 [177Lu] and Actinium-
225 [225Ac], respectively [9–11]. Moreover, the conjugation of diagnostic and therapeutic
radionuclides onto the same nanostructure provides theranostic capabilities [12,13]. Finally,
the functionalization of these nanoparticles with various moieties transforms them into
multimodal theranostic or therapeutic systems [14,15]. For example, radiolabeled particles
that incorporate drugs can be used for image-guided drug delivery or controlled release
with synergistic therapeutic effects (e.g., by combining radio- and chemotherapy) [16–18].
Magnetic iron oxide nanoparticles (MIONs) are among the most attractive theranostic
nanoplatforms [19]. Apart from the advantages mentioned above, MIONs have exceptional
characteristics that make them suitable for various uses in cancer management [20]. Firstly,
due to their spin-active lattice and high biocompatibility, MIONs are clinically used as
T2-contrast enhancement agents in MRI [21–23] and have great potential in magnetic force-
guided drug delivery and cancer treatment with magnetic hyperthermia [24–26]. Secondly,
the synthesis of MIONs by chemical procedures is facile and enables highly controllable
size, composition, and magnetic properties [27]. Finally, radiolabeled MIONs can play the
role of dual modality PET/MR or SPECT/MR imaging agents, combining the sensitivity of
nuclear medicine modalities with the anatomical details provided by MRI, thus improving
cancer diagnosis [15,27–29].
The delivery of MIONs to tumors is achieved mainly by active and passive targeting. For
active targeting, the particle surface is functionalized with ligands (small molecules, peptides,
monoclonal antibodies) that recognize specific molecular cancer targets [18,29–31]. Passive
tumor targeting is based on the enhanced permeability and retention effect (EPR), which
comprises the extravasation of nanoparticles through the intercellular pores of tumor vessels
(leaky vasculature) and their retention in tumor interstitial space due to the abnormally poor
lymphatic drainage [32,33]. Passive accumulation of MIONs in tumors is greatly determined
by their retention time in blood circulation, which in turn can be controlled by particle size
and surface chemistry tuning. Nanoparticles smaller than 10 nm are rapidly cleared from
the bloodstream via the kidneys, while particles over 200 nm are quickly covered by plasma
proteins, namely opsonins; recognized by monocytes and macrophages; and finally undergo
phagocytosis in the mononuclear phagocyte system (MPS) organs (mainly liver, spleen, and
bone marrow). Hence, nanoparticle size between 10 and 200 nm is mostly suitable for a long
circulation time, which increases the possibility for effective tumor uptake [27,34,35]. With
respect to surface modification, the presence of neutral and hydrophilic polymeric coatings
(e.g., PEG, dextran, and silica) has been correlated with reduced nonspecific interactions
and thus stealthy delivery [36,37]. Moreover, suitable coating imparts colloidal stability
(agglomeration avoidance), low toxicity, and protection of the magnetic properties of the
MIONs, necessary characteristics for a cancer targeting candidate [36].
Early cancer diagnosis remains a key factor for curative treatment and increased
survival [38]. PET, based on the detection of coincidence photons produced by positron-
electron annihilation, is the most sensitive imaging technique able to quantify the acquired
information, thus offering early detection, which leads to improved decision making [39].
The choice of the radioisotope is a crucial parameter when considering the design of an
effective imaging agent. While 18F is the most common PET isotope in the clinic, 68Ga has
been at the center of scientific studies for the last 20 years due to its favorable characteristics.
68Ga mainly decays by positron emission (88.8%) to stable 68Zn, with a half-life of 67.83 min.
The high emission probability of annihilation photons results in a strong signal for detection
with PET systems, while the relatively low yield of other γ-photons and short half-life are
positive features from the radiation protection point of view. Another advantage of 68Ga is
its easy onsite availability from a 68Ge/68Ga generator (T1/2 of 68Ge = 270.8 days); hence,
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there is no need of a locally or nearby-installed cyclotron for everyday production. Lastly,
thanks to its versatile coordination chemistry, 68Ga(III)—the prevalent state in aqueous
solutions—conjugates with a variety of ligands that contain functional groups, such as
carboxylates, phosphonates, and amines, to form thermodynamically stable complexes
with various agents for imaging applications [2]. All the above were the driving force
of a plethora of studies concerning 68Ga-labeled nanoparticles, the results of which are
promising for new 68Ga-based cancer imaging probes in the future [3,5–7].
In this study, two different approaches were explored to develop MIONs radiola-
beled with 68Ga. The MIONs were initially functionalized with the poly(methacrylic
acid)-graft-poly(ethyleneglycol methacrylate) copolymer (p(MAA-g-EGMA)). The primary
idea behind the design and synthesis of these MNPs was to improve stability and bio-
compatibility, as well as to provide a platform for the development of a theranostic agent.
Then, the chelating agent NODAGA-NHS was conjugated onto the surface of the MIONs
(MagP-NODAGA) to form a chelate complex with 68Ga in the chelator-mediated approach.
In the chelator-free approach, 68Ga was directly incorporated onto the surface of the MIONs
(MagP) by taking advantage of its affinity towards the carboxylic groups of the copolymer
coating. In vitro stability studies were performed with [68Ga]Ga-MIONs to assess the
stability of the NPs in phosphate-buffered saline (PBS) and human serum, while in vitro
cytotoxicity studies of the PEGylated MIONs were performed to evaluate their cytotoxicity.
To examine the potential of the [68Ga]Ga-MIONs as radiotracers for early cancer detection,
biodistribution studies were conducted in normal mice, while initial micro-PET imaging
studies were also performed on an experimental tumor model.
2. Materials and Methods
68Ga is a high-energy positron emitter, which presents serious health threats and
requires special radioprotective precautions during handling to reduce the risk of harm.
All radiolabeling procedures and work associated with radiolabeled compounds was
conducted in a radiochemistry facility which has all the necessary infrastructure, expertise,
and licensing to safely conduct experiments with radioisotopes.
Materials used for the synthesis of the MIONs were purchased from Lab NV
(FeSO4 × 7H2O), Carlo Erba (37% HCl), Aldrich (tris(2aminoethyl)amine and N,N′-diisopr-
opylcarbodiimide), Acros Organics (DMF), and CBL Patras (hydroxybenzotriazole). The
chelating agent NODAGA-NHS was acquired from CheMatech (Dijon, France). Ultra-
pure 3D-H2O with conductivity ~1 µS/cm from an ELGA MEDICA apparatus was used
for all the experiments. Additionally, NaOH and NaCl were from Merck chemicals and
NH4OH (30%, for analysis) from Carlo Erba (Sabadell, Barcelona)). It is noted that all other
chemicals not specified were supplied from Sigma-Aldrich (Darmstad, Germany).
The buffer used for radiolabeling was prepared from trace-free reagents (Sigma-
Aldrich). The 4T1 breast cancer cell line was acquired from the cell bank of the Laboratory
of Radiobiology, Institute of Nuclear & Radiological Sciences and Technology, Energy &
Safety, NCSR “Demokritos”. Cells were free of mycoplasma contamination, as judged
visually under microscope observation and by regular 4′,6-diamidine-2′-phenylindole dihy-
drochloride (DAPI) staining of the cell cultures. The media for the cultures were purchased
from Biowest (Riverside, MO, USA), and the MTT reagent (3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyl-tetrazolium bromide) was obtained from Applichem (Darmstad, Germany).
Optical density measurements in in vitro experiments were conducted using a LabSys-
tems Multiskan RC Microplate Reader (Thermo Fisher ScientificWaltham, MA, USA). A
lower-activity commercial Ge-68/Ga-68 generator was acquired from Eckert & Ziegler
(Berlin, Germany). Water for injection was purchased from DEMO S.A. All other reagents
and solvents used in these studies were obtained from commercial sources without fur-
ther purification. Radioactivity of the [68Ga]GaCl3 and the radiolabeled nanoparticles
was measured using a dose calibrator (Capintec, Ramsey, NJ, USA). Whatman Grade 1
chromatography paper was purchased from Sigma-Aldrich and, along with a Radio-TLC
Scanner (Scan-Ram, LabLogic, Sheffield, UK), was used in the determination of radiolabel-
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ing yield/purity and in vitro stability studies. Water was deionized to 18 MΩ·cm using
an Easypure water filtration system (Barnstead International, Dubuque, Iowa). A gamma
scintillation counter, Cobra II, Canberra, Packard, was used to measure the radioactivity of
each of the organ and blood samples in ex vivo biodistribution studies.
Animals used for the biodistribution studies were obtained from the breeding facilities
of the Institute of Biosciences and Applications, NCSR “Demokritos”. Our experimental
animal facility is registered according to the Greek Presidential Decree 56/2013 (Reg.
Number: EL 25 BIO 022), in accordance with the European Directive 2010/63, which
is harmonized with national legislation, on the protection of animals used for scientific
purposes. All applicable national guidelines for the care and use of animals were followed.
The study protocol was approved by the Department of Agriculture and Veterinary Service
of the Prefecture of Athens (Protocol Number: 1607/11-04-2018). These studies have been
further approved by our institutional ethics committee, and the procedures followed are in
accordance with institutional guidelines.
PET scans were performed using a Mediso scanner NanoScan PC, with 8 detector
modules. This type of scanner has an axial field of view of 98.6 mm and a spatial reso-
lution of 0.8 mm at the center of the scanner, employing the Tera-Tomo 3D PET iterative
reconstruction algorithm. Prior to PET imaging, a CT scan was performed for attenuation
correction and anatomic localization. The X-ray beam energy was set at 50 kVp, the ex-
posure time at 300 msec, and current at 670 µA. The number of projections per rotation
was 480, and the slice thickness was 250 µm. PET and CT data were reconstructed using
Nucline software version 3.00.021.0000. The PET image reconstruction was performed
using a version of 3D OSEM algorithm (Tera-Tomo 3D PET image reconstruction algorithm)
with voxel dimensions of 0.4 × 0.4 × 0.4 mm (size of image matrix 83 × 98 × 392). Dead
time, decay, scatter, attenuation, and axial sensitivity corrections and normalization were
applied to PET data. Image analysis was performed with the Mediso InterView Fusion
software package version 3.00.039.0000 BETA.
2.1. Synthesis of MIONs
2.1.1. Synthesis and Functionalization of Magnetic Nanoparticles
The magnetic nanoparticles were synthesized following hydrolytic alkaline precipita-
tion from a ferrous salt precursor route in the presence of p(MAA-g-EGMA) copolymer as
previously described, with slight modifications [40]. In brief, FeSO4 × 7H2O (1.44 g, 99+%)
was dissolved in 20 mL of deionized H2O (containing 60 µL of 37% HCl). The copolymers
of poly(methacrylic acid)-graft-poly(ethyleneglycol methacrylate) were synthesized by rad-
ical copolymerization of methoxy-PEG-methacrylate with methacrylic acid, as previously
described [41]. P(MAA-g-EGMA) (300 mg) was dissolved in dH2O (60 mL) and 4 mL NH3
(30%) was added to the polymer solution. The mixture was heated at 50 ◦C under magnetic
stirring and the reaction stopped after 1 h and 30 min. The product was purified from
byproducts by centrifugation at 18,000 rcf for 30 min and subsequent redispersion of the
pellet in dH2O, followed by sonication and vortexing. The procedure was repeated thrice.
A final mild centrifugation (2100 rcf, 15 min) was performed for the fractionation of the
product (MagP), in order to remove larger aggregates.
Functionalization of MagP with tris(2aminoethyl)amine (96%) was performed accord-
ing to the following protocol. The acid form of MagP was prepared by dialysis in H2O at pH
4 for 3 days, exchanging the bath medium frequently. The MagP nanoparticles were then
transferred in DMF by centrifugation and subsequent redispersion of the pellet in DMF.
The process was repeated thrice. DIC (N,N′-diisopropylcarbodiimide) and HOBt (hydroxy-
benzotriazole) coupling reagents were used for the conjugation of tris(2aminoethyl)amine
onto the carboxylates of the nanoparticles. Conjugation reagents were used in a molar
excess of 3.3 with respect to the carboxylates present on MagP, while triamine was used
in a molar excess of 3. Finally, the amine-functionalized nanoparticles were mixed with
the amine-reactive chelating agent NODAGA-NHS (ester of a macrocyclic chelator NODA
derivative with N-hydroxysuccinimide) and left for overnight magnetic stirring, resulting
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in the chelator-modified MagP-NODAGA nanoparticles. After each coupling reaction,
nanoparticles were thoroughly washed through centrifugation and redispersion in DMF.
The final product was redispersed in distilled H2O and dialyzed for several days with
dialysis membranes in order to remove DMF traces and reaction byproducts.
2.1.2. Hydrodynamic Diameter and Zeta Potential Measurements
Dynamic light scattering (DLS) was performed on aqueous dispersions of ∼0.01%
w/v in Fe2O3, where scattered light was collected at a fixed angle of 173◦ with a Malvern
Instrument ZetaSizer Nano and with a 4-mW He−Ne laser, operating at a wavelength of
633 nm. The hydrodynamic diameters (Dh) and the reported polydispersity index (PDI)
values are the mean of three measurements, where each measurement was the sum of
12 correlograms and fitting procedures. The cumulants analysis method was applied,
and the Dh average values reported are the z-average mean Dh, unless otherwise stated.
Electrokinetic measurements for the determination of the mobility and zeta-potential (ζ-p)
values of the suspensions were performed using the same instrument as the average of
100 runs with the phase analysis light scattering mode, after equilibration at 25 ◦C.
2.1.3. Thermogravimetric Analysis (TGA)
The polymer content in the hybrid materials was determined with thermogravimetric
measurements (TA Instruments, Q500). Measurements were performed under N2 flow at a
heating rate of 10 ◦C/min from room temperature to 700 ◦C.
2.1.4. Transmission Electron Microscopy (TEM)
Samples for TEM were prepared by casting a droplet of a dilute aqueous suspension
(0.01% w/v in Fe2O3) of the hybrids on copper grids coated by Formvar carbon film.
Micrographs were obtained by a JEOL, JEM-2100 instrument operating at 200 kV.
2.1.5. Magnetophoretic Evaluation
The magnetophoretic experiments were performed using a Hitachi Digilab U-2800
spectrophotometer, by inserting a cylindrical Nd−Fe−B magnet (diameter = 20 mm,
thickness = 10 mm) next to the cuvette holder at a distance of 2 mm, as previously de-
scribed [40]. The absorbance of the magnetic nanoparticles was recorded every 100 s for
7000 s at 450 nm. The concentration of all the magnetic colloids in all experiments was set
at 0.012% w/v Fe2O3.
2.2. Cell Cultures
4T1 cells (murine mammary carcinoma) were grown in RPMI-1640 Medium (RPMI) of
pH 7.0 to 7.4, supplemented with fetal bovine serum (FBS) to a final concentration of 10%,
100 U/mL of penicillin, 2 mM glutamine, and 100 µg/mL of streptomycin. Cell cultures
were maintained in flasks and were grown at 37 ◦C in a humidified atmosphere of 5% CO2
in air. Subconfluent cells were detached using a 0.25% trypsin-0.53 mM ethylenediaminete-
traacetic acid (EDTA) solution, and the subcultivation ratio was 1:8–1:10.
2.3. MTT Toxicity Assay
In vitro cytotoxicity of the prepared MagP and MagP-NODAGA MIONs against
4T1 cells was evaluated by the MTT colorimetric assay. MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) is a yellow tetrazolium salt that is reduced by
metabolically active cells in mitochondria, via the action of dehydrogenase enzymes. The
resulting product, a purple formazan, can be solubilized and quantitatively determined
by spectrophotometry. Absorbance is proportional to the concentration of formazan, thus
to the concentration of active cells. The inability of dead cells to metabolize MTT leads to
reduced absorbance, which subsequently can be used as an indicator of cytotoxicity. For
the toxicity assay, cells were seeded in 96-well plates (15 × 103 cells/well) and allowed
to grow overnight at 37 ◦C in a 5% CO2 incubator. Cells were incubated with increasing
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concentrations of both complexes (1.0625, 3.125, 6.25, 12.5, 25, and 50 µg (Fe2O3)/mL) for
24 h [42]. The medium was then removed and replaced with 100µL of MTT dissolved in
RPMI (1 mg/mL). After a 4-h incubation period, the MTT solution was carefully aspirated,
and formazan crystals were solubilized with 100µL of isopropanol. Absorbance was
recorded at 540 nm. All experiments were performed in triplicate, and the results were
calculated as noted from the following equation: cell viability (%) = (mean optical density
(OD) in treatment group/mean OD in control group) × 100.
2.4. Labeling of MIONs with 68Ga and Radiochemical Analysis
For the labeling of the magnetic nanoparticles, 68Ga was initially eluted from a
68Ge/68Ga generator with 7 mL 0.1 N HCl and trapped onto an acidic cation-exchange
resin. Metal impurities were removed by passage of 1 mL of a solution containing acetone
(80 v/v%) and 0.15 M HCl (20 v/v%). Desorption of purified 68Ga was accomplished
with 400 µL of a solution of acetone (97.6 v/v%) and 0.15 M HCl (2.4 v/v%) [43]. Then, a
mixture containing 350 µL of 0.5 M sodium acetate buffer pH 4, 50 µL of MIONs suspension
(CMagP = 2.8 mg/mL, CMagP-NODAGA = 1.1 mg/mL), and 100 µL of [68Ga]GaCl3 (~40 MBq)
was vortexed and incubated at 70 ◦C for 30–120 min. The activities of the eluate and label-
ing mixture were measured with a dose calibrator. The radiochemical yield (RCY) of the
labeled MIONs was determined at three time points after incubation (30, 60, and 120 min)
by thin layer chromatography, using Whatman No 1 sheets as the stationary phase and
0.1 M citric acid as the mobile phase. In this chromatography system, the [68Ga]Ga-MIONs
remain at the application point, while unbound 68Ga ions move to the solvent front [3]. The
latter was verified by a control experiment, where the MIONs suspension was replaced by
an equal volume of ultrapure water, while all the other constituents of the sample remained
the same. The developed sheet was scanned by a radio-TLC detector and the %RCY of
[68Ga]Ga-MIONs was calculated as: 100 × (counts at application point/total counts). Data
collection and analysis were performed with Laura software v. 5.0.4.29 (Sheffield, UK).
2.5. In Vitro Stability Studies
In vitro stability of the [68Ga]Ga-MIONs was tested in phosphate-buffered saline (PBS)
and human serum. For this purpose, 20 µL of radiolabeled nanoparticles were incubated with
180 µL PBS pH 7.4, while shaking at room temperature. The serum stability studies were
conducted using human serum (Sigma–Aldrich) according to the procedure followed with
PBS, except for the incubation temperature (37 ◦C). The stability was evaluated at 30, 60, and
120 min by radio-TLC (as described above) and the experiments were performed in triplicate.
2.6. Animal Models
For the animal experiments, female normal Swiss albino and athymic SCID mice were
used. The animals were housed in air-conditioned rooms under a 12-h light/dark cycle
and allowed free access to food and water. For the development of experimental tumors,
1 × 106 4T1 mouse mammary carcinoma cells were subcutaneously inoculated into the
front left limb of SCID mice. Studies were carried out on the 6th day after cell inoculation.
2.7. Ex Vivo Biodistribution Studies
The biological behavior of [68Ga]Ga-MagP and [68Ga]Ga-MagP-NODAGA MIONs was
evaluated in normal Swiss mice (20–30 g) as well as in SCID mice (15–25 g) bearing 4T1 tumors
(n = 3–5 animals per time point). According to the experimental protocol, 100 µL/~300 kBq
of diluted radiolabeled MIONs suspension (containing 1.4 µg of [68Ga[Ga-MagP/0.55 µg
[68Ga]Ga-MagP-NODAGA MIONs) (dilution 1:20 in water for injection) was counted in a dose
calibrator and administered to the animals via the tail vein. At 30, 60, and 120 min postinjection,
the animals were euthanized, and the organs and tissues of interest (including the tumor, in
the case of the tumor model) were collected, weighed and measured in an automatic gamma
counter. For the calculation of the injected dose in each animal, the radioactivity remaining in
the tail was subtracted, and a standard solution was used. All measurements were corrected
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for background and radioactive decay. Finally, the accumulation of the radiolabeled MIONs
in organs and tissues at each time point was expressed as the mean percentage of injected
dose per gram ± standard deviation (% ID/g ± SD).
2.8. In Vivo Imaging Studies (Pilot Studies)
In order to further assess the passive accumulation of [68Ga]Ga-MIONs in tumor-
bearing mice, in vivo micro-PET scans were performed on a 4T1 tumor model. Tumor-
bearing mice were fasted for a period of 12 h prior to imaging. The PET studies were
conducted using 2% isoflurane anesthesia in oxygen at 0.8 lt/min. The lateral tail vein of the
mouse was injected with 100µL/7.42MBq of [68Ga]Ga-MagP. Radiotracer uptake time was
120 min p.i. and was followed by a 20-min PET static scan. During uptake time, the animal
was anesthetized, and its body temperature was maintained at 36 ◦C on the scanner bed.
2.9. Statistical Analysis
The data are presented as means ± standard deviations (SD). For the in vitro stability
and biodistribution studies, the data were compared using an unpaired t-test with a
significance level of p < 0.05. Asterisks indicate the statistical significance of the difference
between the results (* p < 0.05, ** p< 0.01, *** p < 0.001). Absence of asterisks denotes a
nonsignificant statistical difference. Analyses were performed using GraphPad Prism (San
Diego, CA, USA) and Matlab 9.2 (R2017a) (Santa Rosa, CA, USA) software.
3. Results and Discussion
3.1. Synthesis, Functionalization, and Magnetophoretic Evaluation of MIONs
The synthesis of the hybrid MIONs was realized by hydrolytic condensation of a
single ferrous precursor in the presence of the p(MAA-g-EGMA) copolymer acting as the
surface functionalizing agent through a simple self-assembly process. The carboxylate
groups of the methacrylic monomers coordinate with the Fe ions of the growing MIONs,
while the PEG polymer chains mainly populate the outer corona, forming colloidal clusters,
as previously observed [40,44]. The p(MAA-g-EGMA) copolymer has a high content of
anionic carboxylic sites, facilitating the effective functionalization with the chelating agent
for 68Ga (Figure 1).
Figure 1. The steps followed for the synthesis of MagP MIONs and the radiolabeled derivatives through chelator-
free or chelator-mediated radiolabeling. The structure of the PEG-branched copolymer of poly(methacrylic acid)-graft-
poly(ethyleneglycol methacrylate) is also shown.
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TEM images (Figure 2a) confirmed the growth of nanoparticles with multiple nanocrys-
tallites forming small clusters of 30–40 nm in diameter due to polymer bridging. The
synthesized MagP MIONs displayed an average Dh of 87 nm (Figure 2b), which is suit-
able for passive targeting of cancerous tissues through the EPR effect after intravenous
administration [45]. Electrokinetic measurements showed a negative ζ-p of −36 mV at
physiological pH (Figure 2c), due to the presence of the negatively charged –COO− groups
of the polymer. The negative ζ-p, along with the PEG chains of the polymer coating,
provides a combination of strong electrosteric and steric colloidal stability. This was further
corroborated by stability assays in PBS, where MIONs perfectly retained their hydrody-
namic diameter after incubation for several hours in PBS (Figure 2d). This characteristic
indicates effective steric stabilization, which can prolong the blood circulation time of the
nanoassemblies when administered in vivo. The polymer content of the MagP nanoparti-
cles was estimated through thermogravimetric analysis (TGA, Figure 3a) under a N2 stream
at 18 wt.%. Thus, the particularly high 82 wt.% magnetic content in the MagP MIONs
ascribes strong magnetic properties to the colloids. Magnetophoretic experiments demon-
strated the effective manipulation of nanoparticles through the application of external
magnetic gradients. The freshly synthesized MagP MIONs displayed almost identical be-
havior compared to previously reported synthesized batches with similar physicochemical
characteristics (Dh = 85 nm) and a high saturation magnetization (Ms) of 80 emu/g [40,46].
For comparison, a sample composed of 6-nm MIONs, and thus of significantly lower
magnetization (~35 emu/g), is also included in Figure 3b to demonstrate the difference in
magnetic response.
Figure 2. (a) TEM image; (b) hydrodynamic diameter distributions from DLS measurements; (c) zeta-
potential distribution for the MagP nanoparticles; (d) hydrodynamic diameter distributions from
DLS measurements for the MagP-NODAGA functionalized MIONs. The lower Dh of MIONs in PBS
is attributed to the contraction of the polyelectrolyte chains due to the high salinity.
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Figure 3. (a) Thermogravimetric analysis for the MagP MIONs; (b) magnetophoretic response of
the MagP MIONs compared to samples composed of small magnetic nanocrystals with low Ms
(~35 emu/g).
The abundant carboxylic groups of the MagP MIONs were utilized for the modification
of nanoparticles with a triamine. This step is required for the subsequent conjugation with
the amine-reactive chelator NODAGA-NHS ester. The resulting MagP-NODAGA MIONs
exhibited a slightly larger Dh of ~108 nm (Figure 4).
Figure 4. Hydrodynamic diameter distributions from DLS measurements for the MagP-
NODAGA MIONs.
3.2. Cytotoxicity of MagP and MagP-NODAGA MIONs
The MTT assay was conducted to assess the cytotoxicity of the MagP and MagP-
NODAGA MIONs against 4T1 breast cancer cells. Figure 5 summarizes the experimental
data after 24 h of cell exposure to different concentrations of the nanoparticles. MagP
were not cytotoxic, and even at the highest tested concentration of 50 µg (Fe2O3)//mL,
a viability of about 90% was observed. However, in the case of MagP-NODAGA, cell
viability values tended to decrease gradually from 80% for the lower concentration of
1.0625 µg (Fe2O3)//mL) to 71% at the highest concentration of 50 µg (Fe2O3)/mL. The
slightly higher toxicity of MagP-NODAGA compared to MagP MIONs could possibly be
attributed to the presence of the NODAGA-NHS chelating agent in the former species.
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Figure 5. MTT assay of 4T1 cells treated with different concentrations of MagP and MagP-NODAGA
MIONs. Zero concentration corresponds to the negative control for both NPs (no nanoparticles
present in the sample). Mean values (n = 3) and the SD (bars) are shown.
3.3. Labeling of MIONs with 68Ga
The labeling procedure of the magnetic nanoparticles consisted of the incubation of
a mixture of [68Ga]GaCl3 eluate and nanoparticles at 70 ◦C, pH 4 (as described above).
These conditions were finalized after preliminary experiments were conducted, taking
into account the existing literature on gallium chemistry. In aqueous solutions, gallium is
primarily found in the oxidative state +3. Ga(III), as a hard Lewis acid, binds to electron
donors, such as oxygen and nitrogen. However, bonding is not favored by extreme pH,
since in a strongly acidic environment, the protonation of donor atoms occurs, and insoluble
gallium hydroxides are formed at high pH values. Thus, the pH range 3–5 is considered
as most suitable for labeling with gallium [2,3]. In our study, MagP-NODAGA MIONs
were labeled by chelate complex formation of 68Ga(III) with NODAGA-NHS through the
3 nitrogen atoms of the macrocyclic ring and the 3 oxygen atoms of the carboxylate groups
of the chelator [47]. On the contrary, the labeling of MagP MIONs was direct, through the
coordination of the radioisotope with the carboxylates of the copolymer p(MAA-g-EGMA).
According to the radio-TLC analysis results, the radiochemical yields were > 92% for
the MagP-NODAGA MIONs and > 95% for the MagP MIONs after 30 min of incubation
(Figure 6). Doubling the reaction time resulted in no significant improvement. Control ex-
periments, conducted using ultrapure water instead of nanoparticle suspension, confirmed
the efficacy of the labeling, as > 96% of the radioactivity was detected at the solvent front,
where unbound 68Ga ions migrate (Figure 7).
Overall, the labeling protocol followed resulted in highly efficient radiolabeling of
both groups of magnetic nanoparticles with 68Ga. Labeling was achieved rapidly (in
30 min), which is very important, as fast reactions are required taking into account the
short half-life of 68Ga. Moreover, the conjugation of 68Ga to MagP MIONs indicates that
the macrocyclic chelator NODAGA-NHS is not necessary for the successful radiolabeling
of these nanostructures.
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Figure 6. Radio-TLC chromatograms of 68Ga labeling of: (a) MagP-NODAGA and (b) MagP MIONs.
The peak at the spot area (first 30 mm) is attributed to the radiolabeled MIONs, whereas at the front,
a small amount of unbound 68Ga is detected. These results are acquired after 30 min of incubation.
Figure 7. Radio-TLC chromatogram of a control experiment (30 min incubation). In the absence of
nanoparticles, free 68Ga ions move to the front; thus, the highest amount of radioactivity is detected
in this area.
3.4. In Vitro Stability of [68Ga]Ga-MIONs
Stable coordination of 68Ga to the nanoparticles, for an adequate time after their
administration, is important for their effectiveness as imaging agents. In vivo, free 68Ga
binds to plasma proteins and, generally, is subject to nonspecific interactions [4]. Thus,
under conjugate instability, the acquired PET images depict the biodistribution of the
unbound radioisotope and not the areas of nanoparticle accumulation.
In vitro stability of radiolabeled nanoparticles is indicative of their corresponding
in vivo behavior. For this reason, before proceeding to animal experiments, the stability of
[68Ga]Ga-MIONs was assessed in PBS and human serum at 3 time points, up to 120 min, in
an attempt to simulate physiological conditions.
After radio-TCL analysis, it was found that 78.99± 4.27% of [68Ga]Ga-MagP-NODAGA
MIONs remained intact after 2 h of incubation in PBS, while the respective percentage for
[68Ga]Ga-MagP MIONs was 82.59 ± 10.48%. In human serum, the stability of [68Ga]Ga-
MagP-NODAGA and [68Ga]Ga-MagP MIONs was 84.54 ± 10.53% and 91.86 ± 1.46%,
respectively, at 120 min. It is noted that for both nanostructures, the stability results
between time points were not statistically different, with the exception of [68Ga]Ga-MagP-
NODAGA in PBS (Figure 8).
The satisfactorily high stability of both [68Ga]Ga-MIONs, especially in human serum,
which is in accordance to similar studies reported in the literature [5–7], allowed us to
proceed to biodistribution studies in mice models.
3.5. Ex Vivo Biodistribution Studies of [68Ga]Ga-MIONs
In order to evaluate the in vivo kinetics of [68Ga]Ga-MIONs, ex vivo biodistribution
studies were performed in normal and 4T1 tumor-bearing SCID mice. The aim of these
studies in normal mice is the assessment of the pattern of distribution of the MIONs in
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organs and tissues, as well as their excretion route. Biodistribution experiments in tumor-
bearing mice were conducted in order to investigate the accumulation potential of the
developed [68Ga]Ga-MIONs in solid tumors through passive targeting.
Figure 8. Radiochemical stability of [68Ga]Ga-MIONs in: (a) PBS and (b) human serum. A statistical
difference was found between stability results of [68Ga]Ga-MagP-NODAGA MIONs in PBS at 60 and
120 min (p < 0.01) and 30 and 120 min (p < 0.05).
3.5.1. Ex Vivo Biodistribution Studies of [68Ga]Ga-MIONs in Normal Mice
The biodistribution results, presented in Figure 9, show that the highest accumulation
of [68Ga]Ga-MagP-NODAGA MIONs in normal mice is in the liver and spleen at all time
points (indicatively, 54.86 ± 15.89% and 15.61 ± 0.27% at 120 min p.i., respectively). The
uptake in lungs follows a decreasing pattern, falling from 14.58 ± 3.71% at 30 min p.i. to
4.51 ± 2.73% at 120 min p.i. Low bone accumulation is also observed, which remains stable
throughout the time of study (3.12 ± 1.21%, 2 h p.i.). The retention of [68Ga]Ga-MagP-
NODAGA MIONs in the bloodstream is practically constant, being 2.74 ± 0.63% at 30 min
p.i. and 2.57 ± 0.85% at 120 min p.i. Finally, no major uptake of [68Ga]Ga-MagP-NODAGA
MIONs in other organs is noted.
Figure 9. Biodistribution of [68Ga]Ga-MagP-NODAGA MIONs in normal mice (n = 3–5 mice per time
point). Asterisks indicate the statistical significance of the difference between the results (* p < 0.05,
** p < 0.01, *** p < 0.001). Absence of asterisks denotes a nonsignificant statistical difference.
Regarding [68Ga]Ga-MagP MIONs, accumulation in the liver and spleen (58.55 ± 17.19%
and 34.20 ± 12.52%, 120 min p.i., respectively) does not vary significantly between time
points, whereas in the lungs there is a declining trend, similar to [68Ga]Ga-MagP-NODAGA
MIONs (Figure 10). The presence of [68Ga]Ga-MagP MIONs in blood is stable (indicatively,
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1.32 ± 0.75% at 120 min p.i.). The biodistribution behavior of [68Ga]Ga-MagP in the
remaining organs was similar to that of [68Ga]Ga-MagP-NODAGA MIONs.
Figure 10. Biodistribution of [68Ga]Ga-MagP MIONs in normal mice (n = 3–5 mice per time point).
Asterisks indicate the statistical significance of the difference between the results (* p < 0.05, ** p < 0.01,
*** p < 0.001). Absence of asterisks denotes a nonsignificant statistical difference.
It has been noted that the biodistribution of nanoparticles is highly correlated with
their physicochemical properties, such as size and surface chemistry [48,49]. After their
intravenous administration, nanoparticles > 200 nm in size are rapidly covered by plasma
proteins (opsonins), which are subsequently recognized by cells of the mononuclear phago-
cyte system (MPS), mainly Kupffer cells in the liver and macrophages in the spleen and
bone marrow. As a result, these nanoparticles accumulate in the aforesaid organs, where
they are phagocytosed [27,50]. On the other hand, ultrasmall nanoparticles are not recog-
nized by MPS but are rapidly cleared by renal secretion [50,51]. Both opsonization and renal
clearance can lead to decreased blood circulation, which compromises tumor uptake, hence
the effectiveness of nanoparticles as cancer imaging agents. Another factor that affects the
fate of nanoparticles is surface coating. In general, hydrophilic and neutral nanoparticle
coatings contribute to the evasion of the MPS and thus to longer blood retention and a
higher possibility for passive tumor targeting [36,37]. In our case, [68Ga]Ga-MIONs are
mainly detected in the MPS organs of normal mice, primarily the liver and spleen. This
fact can be attributed to their size and surface charge. [68Ga]Ga-MagP-NODAGA and
[68Ga]Ga-MagP MIONs, with hydrodynamic diameters of 108 and 87 nm, respectively,
follow the behavior of nanoparticles of similar size [5,52]. It is also reported that high
negative nanoparticle surface charge may bring about more interactions with macrophages;
thus, the surface charge of MIONs (−36 mV, at pH 7) may account for their high accu-
mulation in MPS organs [30,53]. While the presence of the hydrophilic p(MAA-g-EGMA)
coating resulted in their high colloidal stability in vitro, it did not inhibit uptake of these
nanostructures in MPS organs in vivo, indicating that a higher molecular weight PEG is
probably needed for effective steric stabilization of these MIONs in vivo. With regard to the
excretion route, a minor accumulation in kidneys and a high liver and spleen uptake show
that [68Ga]Ga-MIONs are mainly cleared by the hepatobiliary system and not by renal
excretion. Overall, the in vivo behavior of [68Ga]Ga-MagP-NODAGA and [68Ga]Ga-MagP
MIONs in normal mice is similar to the biodistribution of nanoparticles with comparable
physicochemical properties [5,52,54]. Despite the high uptake of [68Ga]Ga-MIONs by the
MPS organs, blood retention is satisfactory, which is encouraging for the continuation of
studies in tumor-bearing mice.
3.5.2. Ex Vivo Biodistribution Studies of [68Ga]Ga-MIONs in 4T1 Tumor-Bearing Mice
Studies in pathological mice were performed after the development of 4T1 tumors in
SCID mice, namely on the 6th day after the subcutaneous injection of 1 × 106 4T1 cells in
the front left limb of the animals.
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As expected, the biodistribution of both groups of nanoparticles in pathological mice
follows a similar pattern to that in normal mice (Figures 11 and 12). The organs with the
highest accumulation throughout the time of study were the liver and spleen, followed by
the lungs, where the uptake seems to decrease with time (the reduction was statistically
significant in the case of [68Ga]Ga-MagP MIONs). In bones, the % ID/g of [68Ga]Ga-MagP-
NODAGA MIONs is 4.05 ± 2.59% at 30 min and falls to 2.45 ± 0.01% at 120 min, while
the uptake of [68Ga]Ga-MagP MIONs increases with time but practically reaches the same
level with [68Ga]Ga-MagP-NODAGA MIONs at 120 min p.i. (3.24 ± 0.82%). Radiotracer
uptake in the kidneys, as well as in the other organs, is minor in both groups.
Figure 11. Biodistribution of [68Ga]Ga-MagP-NODAGA MIONs in SCID mice bearing 4T1 tumors
(n = 3–5 mice per time point). Absence of asterisks denotes a nonsignificant statistical difference.
Figure 12. Biodistribution of [68Ga]Ga-MagP MIONs in SCID mice bearing 4T1 tumors (n = 3–5 mice
per timepoint). Asterisks indicate the statistical significance of the difference between the results
(* p < 0.05, ** p < 0.01, *** p < 0.001). Absence of asterisks denotes a nonsignificant statistical difference.
The accumulation of both [68Ga]Ga-MIONs in the tumor follows an increasing trend,
i.e., the % ID/g of [68Ga]Ga-MagP-NODAGA MIONs is 1.39 ± 0.60% at 30 min p.i. and
1.83 ± 0.27% at 120 min p.i., while for [68Ga]Ga-MagP, the observed tumor uptake was
0.74 ± 0.05% and 1.06 ± 0.35% at 30 and 120 min p.i., respectively (a statistically significant
increase was found in the case of [68Ga]Ga-MagP MIONs, as shown in Figure 12).
A factor to be considered during the evaluation of a cancer imaging agent candidate is
the uptake ratio of tumor to organs or tissues (signal-to-noise ratio) because it contributes
to image quality. Specifically, tumor/blood and tumor/muscle ratios are important because
blood and muscle are ubiquitous in the body, and low tumor/tissue ratios can compromise
image quality. In the case of [68Ga]Ga-MagP-NODAGA MIONs, the tumor/blood ratio
at 30 min. p.i. was 0.275 ± 0.002, while the respective ratio for [68Ga]Ga-MagP MIONs
was 0.23 ± 0.03. The accumulation of both complexes in the tumor is higher compared to
that in the muscles at all time points (except for the [68Ga]Ga-MagP MIONs at 30 min p.i.,
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where the two uptakes are almost equal). Accordingly, the tumor/muscle ratios are equal
to or above unity, which is a positive feature for bioimaging applications.
Overall, the biodistribution and tumor uptake of [68Ga]Ga-MIONs in tumor-bearing
mice is in good agreement with results by other groups. As reported, biopolymer-based
nanoparticles of ~110 nm in size and with negative surface charge have a differential
absorption ratio less than 1 in nonspecific tumor targets [55]. In another study, magnetic
nanoparticles of similar size, grafted with p(MAA-g-EGMA) showed accumulation of
0.8–0.9% ID/g in a tumor xenograft after their intravenous administration [44].
A factor that may affect the tumor uptake of [68Ga]Ga-MIONs is the cancer model
studied [17]. It is thought that passive targeting depends on the intrinsic tumor biology,
namely different tumor types may differentiate in their extent of hypervasculature or vessel
architecture [56]. Future studies including tumors other than 4T1 are within our goals.
Several studies propose that the decorating of nanostructures with targeting molecules
presents improved tumor retention [30,57]. Thus, the functionalization of MIONs with
ligands that recognize specific tumor targets could grant higher tumor accumulation to
provide a better imaging performance.
3.5.3. In Vivo Imaging Studies (Pilot Studies)
After evidence of a degree of tumor accumulation was provided by the ex vivo
biodistribution study, a pilot PET imaging study was performed on a 4T1 tumor-bearing
SCID mouse to further evaluate the tumor accumulation of the developed radiolabeled
nanoconstructs. The PET image of a mouse injected with [68Ga]Ga-MagP MIONs showed
radiotracer uptake in the tumor, while the main organs of accumulation were the liver and
spleen (Scheme 1). These results are in direct agreement with the ex vivo biodistribution
results initially performed in tumor-bearing mice (Figures 11 and 12). In vivo assessment
on the PET camera after 120 min p.i. of the radiotracer was not possible, due to the short
half-life of 68Ga.
Scheme 1. PET image of a 4T1 tumor-bearing SCID mouse injected with [68Ga]Ga-MagP MIONs at
120 min p.i.
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4. Conclusions
Magnetic iron oxide nanoparticles were successfully synthesized and surface function-
alized with the poly(methacrylic acid)-graft-poly(ethyleneglycol methacrylate) copolymer
(p(MAA-g-EGMA)), providing colloidal stability and biocompatibility of MIONs, while
at the same time exhibiting the advantage of the diversity of choice for radiolabeling
with 68Ga. In this study, two different approaches were explored to develop 68Ga-labeled
MIONs. For the chelator-mediated approach, the chelating agent NODAGA-NHS was
conjugated onto the surface of the MIONs (MagP-NODAGA) to form a chelate complex
with 68Ga. In the chelator-free approach, 68Ga was directly incorporated onto the surface of
the MIONs (MagP). Both approaches succeeded in the rapid and highly efficient labeling
of MIONs with 68Ga, and stable conjugates were formed. Although ex vivo biodistribution
studies of [68Ga]Ga-MIONs showed high accumulation in the MPS organs, they indicated
satisfactory blood retention at 30, 60, and 120 min p.i. Furthermore, the tumor/muscle
ratios were all above 1. In vivo PET imaging of a mouse injected with [68Ga]Ga-MagP
MIONs showed that the results are in direct agreement with the ex vivo biodistribution
results initially performed in tumor-bearing mice. Finally, the low toxicity of MagP and
MagP-NODAGA MIONs against 4T1 breast cancer cells gives an indication of their in vivo
biocompatibility. These preliminary studies established that [68Ga]Ga-MIONs exhibit
potential for bioimaging applications.
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